Inside at any time regardless of the meal. Tablets should be swallowed whole with water without chewing or crushing. If necessary, administration of the drug at a dose of 5 mg should be divided 10 mg tablet in half.
Prior to initiating therapy with rosuvastatin patient must begin to comply with the standard lipid-lowering diet and continue to observe her during treatment. The dose masteron dosage should be selected individually depending on indications and therapeutic response, taking into account the current recommendations for lipid target levels. The recommended starting dose of rosuvastatin in patients who start taking the drug, or for patients transferred from receiving other HMG-CoA reductase, is 5 or 10 mg 1 time / day.
When selecting the starting dose should be guided by the patient’s cholesterol and take into account the risk of developing cardiovascular complications, as well as the need to evaluate the potential risk of side effects. If necessary, after 4 weeks the dose may be increased.
Patients with severe hypercholesterolemia and at high risk of cardiovascular complications (especially those with familial hypercholesterolemia) in which the desired result was not achieved by administration of a dose of 20 mg during a 4-week therapy, increase the dose to 40 mg should be under medical supervision because of the possible increased risk of side effects. Recommended especially careful monitoring of patients receiving the drug at a dose of 40 mg. After masteron dosage of treatment and / or increasing the dose Tevastor need to control lipid metabolism.
Elderly patients (over 65 years) recommended to start treatment with a dose of 5 mg.
Patients with renal insufficiency, mild or moderate dose adjustment is required .
Do not use this product in any Tevastor doses in severe renal insufficiency (creatinine clearance less than 30 ml / min). Do not use this Tevastor drug in a dosage of 40 mg in patients with moderate renal impairment (creatinine clearance less than 60 mL / min). Patients with moderate renal impairment is recommended initial dose of 5 mg. For patients of Asian race recommended starting dose is 5 mg. Do not use this Tevastor drug at a dose of 40 mg in patients of Asian race.
Contraindicated appointment Tevastor the drug at a dose of 40 mg in patients with factors that may indicate a predisposition for the development of myopathy masteron dosage. At doses of 10 and 20 it is recommended starting dose for patients of this group of 5 mg.
Allergic reactions : seldom – urticaria, pruritus, rash; rarely angioedema, the frequency is unknown – Stevens-Johnson syndrome. From the nervous system: often – headache, dizziness; very rarely – polyneuropathy, memory loss. From the digestive system : often – constipation, nausea, abdominal pain; -neznachitelnoe rare, asymptomatic, transient dose-dependent increase in the activity of “liver” enzymes; very rarely – jaundice, hepatitis; the frequency is unknown – diarrhea. As with other reductase inhibitors, the incidence of adverse events is dose-dependent. On the part of the musculoskeletal system : often – myalgia; rare – myopathy; very rarely – rhabdomyolysis with acute renal failure or without arthralgia. Dose-dependent increase in the activity of creatinine phosphokinase was observed in a small number of patients taking rosuvastatin. In most cases, increasing the activity of was small, asymptomatic and temporary. In the case of increasing the activity of masteron dosage more than 5 times , treatment with rosuvastatin should be suspended. On the part of mochevydelitelnoy system : often – proteinuria for a dose of 40 mg, rarely -proteinuriya for dose 10-20 mg (in most cases, proteinuria decreases or disappears in the treatment process rarely – hematuria). Other : often – asthenic syndrome. Laboratory indicators : increase in the concentration of glucose, bilirubin, gamma-glutamyl activity, alkaline phosphatase, thyroid masteron dosage dysfunction.